Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study
Outcomes nach steroid-sparendem Immunsuppressivum versus Steroid-Monotherapie bei immunvermittelten Nebenwirkungen bei nicht-kleinzelligem Lungenkarzinom (NSCLC) und Melanom: retrospektive Fall-Kontroll-Studie
Cancers · 16.05.2024 · 16 (10) · 1892
DOI: 10.3390/cancers16101892 ↗Auf einen Blick
Bei 167 Patient:innen mit Melanom oder NSCLC führte CS-SSIA nicht zu schlechteren Tumoroutcomes als CS allein. Für Infliximab bei Melanom zeigte sich ein besseres PFS.
Fragestellung
Unterscheidet sich das Tumoroutcome nach Behandlung immunvermittelter Nebenwirkungen mit Kortikosteroid-Monotherapie versus Kortikosteroid plus steroid-sparendem Immunsuppressivum?
Methode
Retrospektive Fall-Kontroll-Studie bei Patient:innen ≥ 18 Jahre mit Melanom oder NSCLC und ≥1 ICI; Matching nach Tumortyp, Stadium und Vorbehandlung; Analyse mit Cox-Regression.
Ergebnisse
167 Patient:innen nach Matching: 132 in der CS- und 35 in der CS-SSIA-Kohorte. Kein signifikanter Unterschied für PFS (HR 0,75; 95 %-KI 0,46–1,23) oder OS (HR 0,82; 95 %-KI 0,46–1,47).
Schlussfolgerung der Autor:innen
Die Kombination von SSIAs mit CS war nicht mit schlechteren Outcomes verbunden als CS allein. Bei Melanom war Infliximab mit verbessertem PFS gegenüber Steroidmonotherapie assoziiert.
Kernaussagen
- PFS und OS unter CS-SSIA nicht schlechter als unter CS allein
- Kein signifikanter Unterschied: PFS HR 0,75; OS HR 0,82
- Bei Melanom zeigte Infliximab ein verbessertes PFS
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Cancers, online erschienen am 16.05.2024. Verfasst von Sharjeel Syed und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Chicago, Chicago, IL 60637, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, University of Chicago.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
The effects of steroid-sparing immunosuppressive agents (SSIAs), used for the treatment of immune-related adverse events (irAEs), on immune checkpoint inhibitor (ICI) antitumor activity is not well known. We compared tumor outcomes of patients who received corticosteroid monotherapy (CS) versus a corticosteroid plus SSIA (CS-SSIA) for irAE treatment, using statistical methods to address immortal time bias.
Methods
We conducted a retrospective case-control study on patients ≥ 18 years with melanoma or non-small-cell lung cancer (NSCLC) treated with ≥1 ICI at a quaternary care center between 1 January 2016 and 11 January 2021. Patients were divided into two cohorts: CS or CS-SSIA. We used propensity score nearest-neighbor matching to match on tumor type, stage, and prior lines of therapy. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included the time from the start of the irAE treatment to the irAE resolution. Hazard ratios (HRs) for PFS and OS were calculated using the Cox proportional hazard regression method with both (1) the time to the steroid and SSIA as time-varying covariates and (2) a binary exposure classification not accounting for the time to the treatment.
Results
A total of 167 patients were included after matching (132 in the CS cohort and 35 in the CS-SSIA cohort). Sixty-six percent of all the patients had melanoma. The most common irAEs requiring treatment were gastroenterocolitis and hepatitis. In an adjusted analysis not accounting for immortal time bias, there were no significant differences in PFS (HR 0.75, 95% CI [0.46–1.23]) or OS (HR 0.82, 95% CI [0.46–1.47]). In analyses using a time-varying treatment indicator, there was a trend toward improved PFS in patients treated with SSIAs (HR 0.54, CI 0.26–1.10). There was no difference in OS (HR 1.11, CI 0.55–2.23). Patients with melanoma who specifically received infliximab had improved PFS compared to patients with CS only, after adjusting for immortal time bias (HR 0.32, CI 0.24–0.43).
Conclusions
The use of SSIAs with CS did not have worse outcomes than CS monotherapy. In melanoma, our findings showed improved PFS for the use of infliximab versus steroid monotherapy for irAEs. Large, prospective, randomized controlled trials are needed to confirm these findings and guide the optimal treatment of irAEs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
- Division of Hematology-Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
- Center for Health and The Social Sciences, University of Chicago, Chicago, IL 60637, USA.
- Mass General Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
- Division of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
ORCID-Profile: Sharjeel Syed, Jacobi Hines, Rachel Baccile, Sherin Rouhani, Pankti Reid
Förderung
- NCATS NIH HHS
- NIH HHS
- University of Chicago
- SECURED (Supporting Early-Career University Researchers to Excel through Disruptions) Steering Committee
- University of Chicago Institute of Translational Medicine’s Clinical and Translational Science
Zitieren
APA
Syed, S., Hines, J., Baccile, R., Rouhani, S., & Reid, P. (2024). Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study. Cancers, 16(10), 1892. https://doi.org/10.3390/cancers16101892
Vancouver
Syed S, Hines J, Baccile R, Rouhani S, Reid P. Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study. Cancers. 2024;16(10):1892. doi:10.3390/cancers16101892
BibTeX
@article{Syed2024,
author = {Syed, Sharjeel and Hines, Jacobi and Baccile, Rachel and Rouhani, Sherin and Reid, Pankti},
title = {Studying Outcomes after Steroid-Sparing Immunosuppressive Agent vs. Steroid-Only Treatment for Immune-Related Adverse Events in Non-Small-Cell Lung Cancer (NSCLC) and Melanoma: A Retrospective Case-Control Study},
journal = {Cancers},
year = {2024},
volume = {16},
number = {10},
pages = {1892},
doi = {10.3390/cancers16101892}
}
EUVIMED